Comparable stake leader
BRISTOL MYERS SQUIBB CO
SEC ownership of COMPUGEN LTD
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001119774.
Disclosed value leader
SILVERARC CAPITAL MANAGEMENT, LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- CGEN on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BRISTOL MYERS SQUIBB CO
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BRISTOL MYERS SQUIBB CO
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001119774
- Issuer location
- Holon, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of COMPUGEN LTD (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BRISTOL MYERS SQUIBB CO
Disclosed value leader
SILVERARC CAPITAL MANAGEM...
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 2.1%
13D/G row: BRISTOL MYERS SQUIBB CO
Showing 1-8 of 50 holder rows.
Quick read
BRISTOL MYERS SQUIBB CO leads the comparable SEC ownership view at 2.1%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BRISTOL MYERS SQUIBB CO's linked filing trail.
Comparable ownership
Top 5
BRISTOL MYERS SQUIBB CO
2.1%
Anat Cohen-Dayag
0.12%
Silberman David
0.04%
Michelle Mahler
0.03%
Sharon Kredo Russo
0.02%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BRISTOL MYERS SQUIBB CO |
13D/G
|
2.1%
|
$2,723,401
1,840,136 shares
|
$0 | 31 Dec 2024 |
| Anat Cohen-Dayag |
3/4/5
Director
|
0.12%
|
$192,260
108,622 shares
|
— | 18 Mar 2026 |
| Silberman David |
3/4/5
Chief Financial Officer
|
0.04%
|
$62,835
35,500 shares
|
— | 18 Mar 2026 |
| Michelle Mahler |
3/4/5
Chief Medical Officer
|
0.03%
|
$40,931
23,125 shares
|
— | 18 Mar 2026 |
| Sharon Kredo Russo |
3/4/5
SVP, Research & Discovery
|
0.02%
|
$34,515
19,500 shares
|
— | 18 Mar 2026 |
| Michele Holcomb |
3/4/5
Director
|
0.02%
|
$26,550
15,000 shares
|
— | 18 Mar 2026 |
| Kinneret Livnat Savitzky |
3/4/5
Director
|
0.01%
|
$23,629
13,350 shares
|
— | 18 Mar 2026 |
| Sanford S. Zweifach |
3/4/5
Director
|
0.01%
|
$22,443
12,680 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$121,604.
Buys
$0
Insiders: 0
Sells
$121,604
Insiders: 2
Net
-$121,604
Shares: -49,125
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 49,125
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 49,125 | $0 | $121,604 | -$121,604 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to COMPUGEN LTD. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Anat Cohen-Dayag
Net 12M change
-$121,604
Latest report
24 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anat Cohen-Dayag | Director | $192,260 | Mixed | 18 Mar 2026 | ||
| Zurit Levine | SVP, Business Development | $94,000 | -$78,670 | -46% | Filing P/S | 24 Apr 2026 |
| Silberman David | Chief Financial Officer | $62,835 | Mixed | 18 Mar 2026 | ||
| Michelle Mahler | Chief Medical Officer | $40,931 | Mixed | 18 Mar 2026 | ||
| Eran Ophir | President and CEO, Director | $36,401 | -$42,934 | -54% | Filing P/S | 24 Apr 2026 |
| Sharon Kredo Russo | SVP, Research & Discovery | $34,515 | Mixed | 18 Mar 2026 | ||
| Michele Holcomb | Director | $26,550 | Mixed | 18 Mar 2026 | ||
| Kinneret Livnat Savitzky | Director | $23,629 | Mixed | 18 Mar 2026 | ||
| Sanford S. Zweifach | Director | $22,443 | Mixed | 18 Mar 2026 | ||
| Gilead Halevy | Director | $20,190 | Mixed | 18 Mar 2026 | ||
| Eran Perry | Director | $17,700 | Mixed | 18 Mar 2026 | ||
| Mathias Hukkelhoven | Director | $17,700 | Mixed | 18 Mar 2026 | ||
| Pierre Ferre | Chief Operating Officer | Mixed | 18 Mar 2026 |
Recent insider transactions for COMPUGEN LTD
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Zurit Levine | CGEN | Ordinary Shares | Sale | -6.37% | $6,400 | $3.20 | -2,000 | 29,375 | 24 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 6.81% | 2,000 | 31,375 | 24 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -3.7% | -2,000 | 52,000 | 24 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Ordinary Shares | Sale | -30.5% | $16,000 | $3.20 | -5,000 | 11,375 | 24 Apr 2026 | Direct |
| Eran Ophir | CGEN | Ordinary Shares | Options Exercise | 44% | 5,000 | 16,375 | 24 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Share Option (right to buy) | Options Exercise | -25.8% | -5,000 | 14,375 | 24 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Ordinary Shares | Sale | -30.5% | $14,521 | $2.90 | -5,000 | 11,375 | 14 Apr 2026 | Direct |
| Eran Ophir | CGEN | Ordinary Shares | Options Exercise | 44% | 5,000 | 16,375 | 14 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Share Option (right to buy) | Options Exercise | -20.5% | -5,000 | 19,375 | 14 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -6.37% | $5,600 | $2.80 | -2,000 | 29,375 | 14 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 6.81% | 2,000 | 31,375 | 14 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -3.57% | -2,000 | 54,000 | 14 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -9.62% | $8,012 | $2.56 | -3,125 | 29,375 | 10 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 10.6% | 3,125 | 32,500 | 10 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -35.7% | -3,125 | 5,625 | 10 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -9.62% | $8,012 | $2.56 | -3,125 | 29,375 | 10 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 10.6% | 3,125 | 32,500 | 10 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -35.7% | -3,125 | 5,625 | 10 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -15.5% | $13,008 | $2.42 | -5,375 | 29,375 | 08 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 18.3% | 5,375 | 34,750 | 08 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -44.3% | -5,375 | 6,750 | 08 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -7.84% | $5,750 | $2.30 | -2,500 | 29,375 | 07 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 8.51% | 2,500 | 31,875 | 07 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -18.4% | -2,500 | 11,125 | 07 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -10.6% | $7,700 | $2.20 | -3,500 | 29,375 | 01 Apr 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 11.9% | 3,500 | 32,875 | 01 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -20.4% | -3,500 | 13,625 | 01 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Ordinary Shares | Sale | -33.1% | $12,413 | $2.21 | -5,625 | 11,375 | 01 Apr 2026 | Direct |
| Eran Ophir | CGEN | Ordinary Shares | Options Exercise | 49.4% | 5,625 | 17,000 | 01 Apr 2026 | Direct | ||
| Eran Ophir | CGEN | Share Option (right to buy) | Options Exercise | -18.8% | -5,625 | 24,375 | 01 Apr 2026 | Direct | ||
| Zurit Levine | CGEN | Ordinary Shares | Sale | -28.8% | $24,187 | $2.04 | -11,875 | 29,375 | 26 Mar 2026 | Direct |
| Zurit Levine | CGEN | Ordinary Shares | Options Exercise | 40.4% | 11,875 | 41,250 | 26 Mar 2026 | Direct | ||
| Zurit Levine | CGEN | Share Option (right to buy) | Options Exercise | -42.4% | -11,875 | 16,125 | 26 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.